指南与共识银屑病与炎症性皮肤病皮肤感染

银屑病及银屑病关节炎系统治疗患者带状疱疹发病率系统综述与疫苗接种共识建议

A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation.
指南 / 共识 · J Am Acad Dermatol · 2019-03-15

美国国家银屑病基金会医学委员会系统检索41项研究,评估银屑病及银屑病关节炎患者系统治疗下的带状疱疹风险并制定疫苗接种共识。结果显示系统使用糖皮质激素、托法替布及生物制剂联合传统合成改善病情抗风湿药增加风险,推荐50岁以上及高风险年轻患者接种重组带状疱疹疫苗。

要点

  • 系统使用糖皮质激素、托法替布及生物制剂联合传统合成DMARDs增加带状疱疹风险
  • 生物制剂或传统合成DMARDs单药治疗未显示增加带状疱疹风险
  • 推荐所有>50岁及<50岁高风险银屑病/PsA患者接种重组带状疱疹疫苗

核心结论

  • 带状疱疹风险取决于疾病严重程度和治疗类别。
  • 推荐所有>50岁银屑病及PsA患者和<50岁高风险患者接种重组带状疱疹疫苗。

研究设计与样本

  • 系统文献检索评估银屑病及PsA患者带状疱疹风险,共41项研究符合纳入标准。
  • 美国国家银屑病基金会医学委员会基于分级证据制定共识建议。

主要发现

  • 系统使用糖皮质激素(强,1)、托法替布(强,1)及生物制剂联合传统合成DMARDs(弱,2a)增加带状疱疹风险。
  • 单药治疗未显示增加带状疱疹风险。
  • 白细胞介素12/23、17、23抑制剂或阿普米司特的风险证据不足(弱,2a)。

关键数值与推荐

  • 推荐所有>50岁银屑病及PsA患者接种重组带状疱疹疫苗。
  • 推荐<50岁使用托法替布、系统糖皮质激素或联合系统治疗的患者接种重组带状疱疹疫苗。
  • <50岁使用其他系统治疗的患者可个体化考虑接种。

临床怎么用

  • 对>50岁银屑病及PsA患者常规推荐重组带状疱疹疫苗接种。
  • 对<50岁使用托法替布、系统糖皮质激素或联合系统治疗者推荐接种。
  • 对<50岁使用其他系统治疗者个体化评估接种。

局限性

  • 研究间存在显著异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Herpes zoster (HZ) incidence is linked to immunosuppression. Patients with psoriasis or psoriatic arthritis (PsA) on systemic therapy might be at an increased risk for HZ. OBJECTIVE: To assess HZ risk in patients with psoriasis and PsA by systemic treatment and provide recommendations regarding HZ vaccination. METHODS: A systematic literature search was performed for HZ in patients with psoriasis and PsA. HZ vaccination guidelines were reviewed, and the medical board of the National Psoriasis Foundation made consensus recommendations in psoriasis and PsA patients using graded evidence. RESULTS: In total, 41 studies met inclusion criteria. Systemic corticosteroids (strong, 1), tofacitinib (strong, 1), and combination therapy with biologic and conventional synthetic disease-modifying antirheumatic drugs (weak, 2a) carry increased HZ risk while monotherapy does not. There is insufficient evidence to determine risk with interleukin 12/23, 17, and 23 inhibitors or apremilast (weak, 2a). Recombinant zoster vaccine is recommended for all psoriasis and PsA patients >50 years old and patients <50 years old on tofacitinib, systemic steroids, or combination systemic treatment. Vaccination of patients <50 years old on other systemic therapies may be considered on a case-by-case basis. LIMITATIONS: There was significant heterogeneity between studies. CONCLUSION: HZ risk depends on disease severity and treatment class. Recombinant zoster vaccine should be given to all psoriasis and PsA patients >50 years old and younger patients at increased risk.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Baumrin E, Van Voorhees A, Garg A, et al. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2019. PMID: 30885757. doi:10.1016/j.jaad.2019.03.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。